Acadia Pharmaceuticals announced the discontinuation of its investigational intranasal carbetocin (ACP-101) following a failed Phase III clinical trial to treat hyperphagia in patients with Prader-Willi syndrome. The 12-week, randomized, placebo-controlled study did not meet its primary endpoint of statistically significant improvement over placebo. This setback removes a potential competitor to Soleno Therapeutics’ Vykat XR, the only approved treatment for hyperphagia in this rare genetic disorder, underscoring the challenges in addressing appetite-related symptoms in PWS sufferers.